Galinpepimut-S

BIOLOGICAL7 trials

Sponsors

Sellas Life Sciences Group Inc., Sellas Life Sciences Group, Memorial Sloan Kettering Cancer Center

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute myeloid leukemia (AML) in second or later complete remission (CR2) or second or later complete remission with incomplete platelet recovery (CRp2)Colorectal CancerMesotheliomaMultiple MyelomaMyelodysplastic Syndromes

Phase 1

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

CompletedNCT01827137

Sellas Life Sciences GroupMultiple Myeloma

Start: 2013-04-30End: 2017-11-06Updated: 2024-09-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

CompletedNCT03761914

Sellas Life Sciences GroupAcute Myelogenous Leukemia, Colorectal Cancer, Ovarian Cancer +2

Start: 2019-09-30End: 2022-10-27Updated: 2024-11-19

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

CompletedNCT04040231

Memorial Sloan Kettering Cancer CenterMesothelioma, Pleural Mesothelioma, Wilms Tumor

Start: 2019-07-24End: 2024-11-14Updated: 2025-05-13

Phase 2

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

CompletedNCT01266083

Sellas Life Sciences GroupAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Start: 2011-01-14End: 2016-09-30Updated: 2024-11-19

Phase 3

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruitingNCT04229979

Sellas Life Sciences GroupAcute Myeloid Leukemia

Start: 2021-02-08End: 2026-12-31Updated: 2025-10-01

A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

Active, not recruitingCTIS2024-516405-23-00

Sellas Life Sciences Group Inc.Acute myeloid leukemia (AML) in second or later complete remission (CR2) or second or later complete remission with incomplete platelet recovery (CRp2)

Start: 2021-06-08Target: 101Updated: 2025-01-16

Unknown Phase

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Sellas Life Sciences GroupAcute Myeloid Leukemia, Myelodysplastic Syndromes

Updated: 2024-12-09

Related Papers

REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission

Future Oncology2024-11-282 citations

Combining a WT1 cancer vaccine (galinpepimut-S) with checkpoint inhibition (nivolumab) in patients with WT1-expressing diffuse pleural mesothelioma (DPM): A phase I study.

Journal of Clinical Oncology2024-06-011 citations

A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.

Journal of Clinical Oncology2023-06-011 citations

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia

Blood Advances2018-01-31158 citations

WT1 heteroclitic epitope immunization following autologous stem cell transplantation in patients with high-risk multiple myeloma (MM).

Journal of Clinical Oncology2017-05-203 citations